Saturday, October 3, 2026

Platinum Futures Bullish Momentum With A 14% Rise In The Last 21 Sessions

Platinum Futures Bullish Momentum With A 14% Rise In The Last 21 Sessions

(VIANEWS) - Platinum (PL) has been up by 14.46% for the last 21 sessions. At 17:52 EST on Wednesday, 22 May, Platinum (PL) is $1,046.50.

Volume

Today's last reported volume for Platinum is 26899, 99.99% below its average volume of 7537211180.57.

Volatility

Platinum's last week, last month's, and last quarter's current intraday variation average was 1.69%, 0.91%, and 1.29%, respectively.

Platinum's highest amplitude of average volatility was 2.12% (last week), 1.19% (last month), and 1.29% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Platinum's commodity is considered to be oversold (<=20).

News about

  • Crude oil roils on Monday, WTI finds then loses $80. According to FXStreet on Monday, 20 May, "A lopsided number of refineries went offline for spring maintenance in 2024, and energy traders had been banking on an uptick in Crude Oil demand after those facilities came back online. ", "A broadly-expected increase in Crude Oil markets from refineries has failed to materialize, meaning supply chains are at risk of getting overrun by production that continues to outpace overall demand. "
  • According to FXStreet on Tuesday, 21 May, "At the time of writing, Crude Oil (WTI) trades at $77.90and Brent Crude at $82.29."
  • According to FXStreet on Wednesday, 22 May, "At the time of writing, Crude Oil (WTI) trades at $77.78and Brent Crude at $81.85."

More news about Platinum (PL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com